Predictive Factors of Chemotherapy Initiation after Biliary Drainage for Advanced Biliary Tract Cancer: A Retrospective Multicenter Study.


Journal

Journal of gastrointestinal and liver diseases : JGLD
ISSN: 1842-1121
Titre abrégé: J Gastrointestin Liver Dis
Pays: Romania
ID NLM: 101272825

Informations de publication

Date de publication:
18 06 2021
Historique:
pubmed: 6 5 2021
medline: 15 1 2022
entrez: 5 5 2021
Statut: epublish

Résumé

In unresectable biliary tract cancers, the management of biliary obstruction is often the first step before introduction of chemotherapy. Our aim was to study the predictive factors of chemotherapy initiation after biliary drainage in a series of patients presenting with advanced biliary tract cancer and obstructive jaundice. Data of all patients treated for unresectable biliary tract cancer with initial biliary obstruction requiring a drainage in six institutions, from January 2009 to January 2019, were retrospectively collected. Among 82 patients included in this study (median age 68 years, men 61%), 48 (59%) received chemotherapy. Median overall survival was 4.9 months (0.2-38.7) in the group of patients who did not receive chemotherapy and 12.2 months (1.9-61.0) in chemotherapy group (HR=2.93; 95%CI: 1.6-5.3; p<0.0001). In univariate analysis, younger age, male gender, Eastern Cooperative Oncology Group (ECOG) score ≤2, high albumin level, low C-reactive protein level, and endoscopic drainage were significantly associated with introduction of chemotherapy. In multivariate analysis, only ECOG score ≤2 at diagnosis (HR=70.4; 95%CI: 4.6-1097.6; p=0.002) and male gender (HR=5; 95%CI: 1.5-16.5; p=0.009), were significant independent predictive factors of chemotherapy introduction. Age and bilirubin level at diagnosis were not significant factors in multivariate analysis. ECOG score ≤ 2 and male gender were the only independent predictive factors of chemotherapy introduction in unresectable biliary tract cancers. Age or initial bilirubin level were not predictors for chemotherapy introduction. These results might help defining the initial therapeutic strategy.

Sections du résumé

BACKGROUND AND AIMS
In unresectable biliary tract cancers, the management of biliary obstruction is often the first step before introduction of chemotherapy. Our aim was to study the predictive factors of chemotherapy initiation after biliary drainage in a series of patients presenting with advanced biliary tract cancer and obstructive jaundice.
METHODS
Data of all patients treated for unresectable biliary tract cancer with initial biliary obstruction requiring a drainage in six institutions, from January 2009 to January 2019, were retrospectively collected.
RESULTS
Among 82 patients included in this study (median age 68 years, men 61%), 48 (59%) received chemotherapy. Median overall survival was 4.9 months (0.2-38.7) in the group of patients who did not receive chemotherapy and 12.2 months (1.9-61.0) in chemotherapy group (HR=2.93; 95%CI: 1.6-5.3; p<0.0001). In univariate analysis, younger age, male gender, Eastern Cooperative Oncology Group (ECOG) score ≤2, high albumin level, low C-reactive protein level, and endoscopic drainage were significantly associated with introduction of chemotherapy. In multivariate analysis, only ECOG score ≤2 at diagnosis (HR=70.4; 95%CI: 4.6-1097.6; p=0.002) and male gender (HR=5; 95%CI: 1.5-16.5; p=0.009), were significant independent predictive factors of chemotherapy introduction. Age and bilirubin level at diagnosis were not significant factors in multivariate analysis.
CONCLUSIONS
ECOG score ≤ 2 and male gender were the only independent predictive factors of chemotherapy introduction in unresectable biliary tract cancers. Age or initial bilirubin level were not predictors for chemotherapy introduction. These results might help defining the initial therapeutic strategy.

Identifiants

pubmed: 33951116
doi: 10.15403/jgld-3120
doi:

Substances chimiques

Bilirubin RFM9X3LJ49

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

254-258

Auteurs

Miloud Azarfane (M)

IMAD, Department of Gastroenterology and Digestive Oncology, University Hospital, Nantes, France. . miloud.azarfane@gmail.com.

Astrid Lièvre (A)

Department of Gastroenterology, CHU Pontchaillou, Rennes 1 University; INSERM U1242, Oncogenesis, Stress and Signaling, Rennes, France. astrid.lievre@chu-rennes.fr.

Hélène Senellart (H)

Integrated Center for Oncology, Centre René Gauducheau, Saint Herblain, France. helene.senellart@ico.unicancer.fr.

Brigitte Dessomme (B)

Department of Public Health, University Hospital, Nantes, France. brigitte.desomme@chu-nantes.fr.

Pauline Guillouche (P)

Department of Gastroenterology, Clinique Jules Verne, Nantes, France. pguillouche@hotmail.com.

Jérémy Meyer (J)

Department of Radiology, University Hospital, Nantes, France. jeremy.meyer@chu-nantes.fr.

Jaafar Bennouna (J)

IMAD, Department of Gastroenterology and Digestive Oncology, University Hospital, Nantes, France. Jaafar.bennouna@chu-nantes.Fr.

Thimothée Wallenhorst (T)

Department of Gastroenterology, CHU Pontchaillou, Rennes 1 University; INSERM U1242, Oncogenesis, Stress and Signaling, Rennes, France. thimothee.wallenhorst@chu-rennes.fr.

Maëva Salimon (M)

IMAD, Department of Gastroenterology and Digestive Oncology, University Hospital, Nantes, France. maeva.salimon@chu-rennes.fr.

Jérôme Gournay (J)

IMAD, Department of Gastroenterology and Digestive Oncology, University Hospital, Nantes, France. jerome.gournay@chu-nantes.fr.

Tamara Matysiak-Budnik (T)

IMAD, Department of Gastroenterology and Digestive Oncology, University Hospital, Nantes, France. tamara.matysiakbudnik@chu-nantes.fr.

Annie Lim (A)

Department of Gastroenterology, Clinique Santé Atlantique, Saint Herblain, France. annie.lim87@yahoo.fr.

Julien Edeline (J)

Centre Eugène Marquis, Oncology Department, Rennes, France. j.edeline@rennes.unicancer.fr.

Yann Touchefeu (Y)

IMAD, Department of Gastroenterology and Digestive Oncology, University Hospital, Nantes, France. Yann.touchefeu@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH